Neurogene completes dosing in Rett syndrome gene therapy trial

NGNE’s real inflection is not the headline dosing completion; it is the de-risking of the registrational narrative before the market had to price in a binary enrollment overhang. In rare disease gene therapy, the stock typically re-rates on proof that trial execution can clear the messiest part of the process; finishing dosing ahead of plan reduces the probability of protocol slippage, site fatigue, and post hoc “we needed more patients” dilution of regulatory confidence. The over-enrollment also modestly improves the quality of the safety database, which matters more than the incremental efficacy signal at this stage because it lowers the odds that reviewers focus on an underpowered safety package.

The second-order issue is that the path to approval now becomes a duration trade, not a near-term data trade. With the primary readout pushed into 2027, the equity will likely oscillate between safety headlines and broader risk appetite; that makes the stock vulnerable to multiple compression if biotech weakens or if any gene-therapy class adverse event emerges elsewhere. The absence of a serious safety signal at the stated dose is supportive, but it also raises the bar: the market will expect a clean, durable effect and any hint of plateauing functional gains in the interim update could reset expectations fast.

Consensus appears to be underpricing the value of commercial optionality relative to clinical certainty. If interim data in mid-2026 show durable functional gains and acceptable tolerability, NGNE can transition from a single-asset development story to a plausible ultra-rare franchise platform, which tends to support a much higher multiple than current fundamentals imply. The contrarian risk is that investors are extrapolating the scarcity premium too aggressively: for Rett, the key question is not whether patients improve, but whether the magnitude and durability are sufficient to justify pricing, payer friction, and eventual real-world adoption in a high-touch delivery setting.